250 related articles for article (PubMed ID: 36102777)
1. Association of IMWG frailty score with health-related quality of life profile of patients with relapsed refractory multiple myeloma in Italy and the UK: a GIMEMA, multicentre, cross-sectional study.
Efficace F; Gaidano G; Petrucci MT; Niscola P; Cottone F; Codeluppi K; Antonioli E; Tafuri A; Larocca A; Potenza L; Fozza C; Pastore D; Rigolin GM; Offidani M; Romano A; Kyriakou C; Cascavilla N; Gozzetti A; Derudas D; Vignetti M; Cavo M
Lancet Healthy Longev; 2022 Sep; 3(9):e628-e635. PubMed ID: 36102777
[TBL] [Abstract][Full Text] [Related]
2. Patient-reported frailty phenotype (PRFP) vs. International Myeloma Working Group frailty index (IMWG FI) proxy: A comparison between two approaches to measuring frailty.
Murugappan MN; King-Kallimanis BL; Bhatnagar V; Kanapuru B; Farley JF; Seifert RD; Stenehjem DD; Chen TY; Horodniceanu EG; Kluetz PG
J Geriatr Oncol; 2024 Mar; 15(2):101681. PubMed ID: 38104480
[TBL] [Abstract][Full Text] [Related]
3. Health-related quality of life in patients with triple-class exposed relapsed and refractory multiple myeloma treated with idecabtagene vicleucel or standard regimens: patient-reported outcomes from the phase 3, randomised, open-label KarMMa-3 clinical trial.
Delforge M; Patel K; Eliason L; Dhanda D; Shi L; Guo S; Marshall TS; Arnulf B; Cavo M; Nooka A; Manier S; Callander N; Giralt S; Einsele H; Ailawadhi S; Popa McKiver M; Cook M; Rodríguez-Otero P
Lancet Haematol; 2024 Mar; 11(3):e216-e227. PubMed ID: 38423700
[TBL] [Abstract][Full Text] [Related]
4. A prospective observational study to assess clinical decision-making, prognosis, quality of life and satisfaction with care in patients with relapsed/refractory multiple myeloma: the CLARITY study protocol.
Efficace F; Boccadoro M; Palumbo A; Petrucci MT; Cottone F; Cannella L; Zamagni E; Niscola P; Kyriakou C; Caravita T; Offidani M; Mandelli F; Cavo M
Health Qual Life Outcomes; 2018 Jun; 16(1):127. PubMed ID: 29914509
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of the frailty characteristics and clinical outcomes according to the new frailty-based outcome prediction model (Myeloma Risk Profile-MRP) in a UK real-world cohort of elderly newly diagnosed Myeloma patients.
Djebbari F; Rampotas A; Panitsas F; Lim WY; Lees C; Tsagkaraki I; Gomes AR; Prideaux S; Chen L; Prodger C; Khera A; Gray N; Ellis L; Sangha G; Eyre TA; Moore S; Kothari J; Ramasamy K
PLoS One; 2022; 17(1):e0262388. PubMed ID: 35015781
[TBL] [Abstract][Full Text] [Related]
6. Geriatric assessment in multiple myeloma patients: validation of the International Myeloma Working Group (IMWG) score and comparison with other common comorbidity scores.
Engelhardt M; Dold SM; Ihorst G; Zober A; Möller M; Reinhardt H; Hieke S; Schumacher M; Wäsch R
Haematologica; 2016 Sep; 101(9):1110-9. PubMed ID: 27479825
[TBL] [Abstract][Full Text] [Related]
7. Performance of the International Myeloma Working Group myeloma frailty score among patients 75 and older.
Murillo A; Cronin AM; Laubach JP; Hshieh TT; Tanasijevic AM; Richardson PG; Driver JA; Abel GA
J Geriatr Oncol; 2019 May; 10(3):486-489. PubMed ID: 30472368
[TBL] [Abstract][Full Text] [Related]
8. Quality of life gains in frail and intermediate-fit patients with multiple Myeloma: Findings from the prospective HOVON123 clinical trial.
Seefat MR; Stege CAM; Lissenberg-Witte BI; Levin MD; Timmers GJ; Hoogendoorn M; Ypma PF; Klein SK; Velders GA; Westerman M; Strobbe L; Durdu-Rayman N; Davidis-van Schoonhoven MA; van Kampen RJW; Dijk AC; Koster A; Silbermann MH; van der Spek E; Beeker A; Erjavec Z; de Graauw NCHP; Leys MBL; Sonneveld P; van de Donk NWCJ; Nasserinejad K; Blommestein HM; Cucchi DGJ; Zweegman S
Eur J Cancer; 2024 Jun; 207():114153. PubMed ID: 38870747
[TBL] [Abstract][Full Text] [Related]
9. Assessment of the psychometric properties of the Spanish version of EORTC QLQ-MY20 and evaluation of health-related quality of Life outcomes in patients with relapsed and/or refractory multiple myeloma in the real-world setting in Spain: results from the CharisMMa study.
Dachs LR; Gaisán CM; Bustamante G; López SG; García EG; Persona EP; González-Calle V; Auzmendi MS; Pérez JMA; González Montes Y; Ríos Tamayo R; de Miguel Llorente D; Bernal LP; Mayol AS; Caro CC; Grande M; Fernández-Nistal A; Naves A; Miguel EMOS
Leuk Lymphoma; 2023; 64(11):1847-1856. PubMed ID: 37539698
[TBL] [Abstract][Full Text] [Related]
10. Measuring Frailty Using Patient-Reported Outcomes (PRO) Data: A Feasibility Study in Patients with Multiple Myeloma.
Murugappan MN; King-Kallimanis BL; Bhatnagar V; Kanapuru B; Farley JF; Seifert RD; Stenehjem DD; Chen TY; Horodniceanu EG; Kluetz PG
Qual Life Res; 2023 Aug; 32(8):2281-2292. PubMed ID: 36935467
[TBL] [Abstract][Full Text] [Related]
11. Mapping EORTC QLQ-C30 and QLQ-MY20 to EQ-5D in patients with multiple myeloma.
Proskorovsky I; Lewis P; Williams CD; Jordan K; Kyriakou C; Ishak J; Davies FE
Health Qual Life Outcomes; 2014 Mar; 12():35. PubMed ID: 24618388
[TBL] [Abstract][Full Text] [Related]
12. Comprehensive geriatric assessment in newly diagnosed older myeloma patients: a multicentre, prospective, non-interventional study.
Yao Y; Sui WW; Liao AJ; Wang W; Chen LJ; Chu XX; Bao L; Cen XN; Fu R; Liu H; Sun CY; Jin FY; Yan H; Wang LQ; Yuan CL; Gao GX; Gao D; Zhang JQ; He JX; Hu JD; Ma LM; Zhang L; Zhou DB; Zou DH; Li J
Age Ageing; 2022 Jan; 51(1):. PubMed ID: 34673897
[TBL] [Abstract][Full Text] [Related]
13. The impact of disease-related symptoms and palliative care concerns on health-related quality of life in multiple myeloma: a multi-centre study.
Ramsenthaler C; Osborne TR; Gao W; Siegert RJ; Edmonds PM; Schey SA; Higginson IJ
BMC Cancer; 2016 Jul; 16():427. PubMed ID: 27387201
[TBL] [Abstract][Full Text] [Related]
14. A comparison of three different approaches to defining frailty in older patients with multiple myeloma.
Isaacs A; Fiala M; Tuchman S; Wildes TM
J Geriatr Oncol; 2020 Mar; 11(2):311-315. PubMed ID: 31326393
[TBL] [Abstract][Full Text] [Related]
15. Health-related quality of life in patients given ciltacabtagene autoleucel for relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b-2, open-label study.
Martin T; Lin Y; Agha M; Cohen AD; Htut M; Stewart AK; Hari P; Berdeja JG; Usmani SZ; Yeh TM; Olyslager Y; Goldberg JD; Schecter JM; Madduri D; Jackson CC; Deraedt W; Gries KS; Fastenau JM; Trudeau JJ; Akram M; Pacaud L; Jakubowiak A; Jagannath S
Lancet Haematol; 2022 Dec; 9(12):e897-e905. PubMed ID: 36215989
[TBL] [Abstract][Full Text] [Related]
16. Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial.
Harrington KJ; Ferris RL; Blumenschein G; Colevas AD; Fayette J; Licitra L; Kasper S; Even C; Vokes EE; Worden F; Saba NF; Kiyota N; Haddad R; Tahara M; Grünwald V; Shaw JW; Monga M; Lynch M; Taylor F; DeRosa M; Morrissey L; Cocks K; Gillison ML; Guigay J
Lancet Oncol; 2017 Aug; 18(8):1104-1115. PubMed ID: 28651929
[TBL] [Abstract][Full Text] [Related]
17. Elderly patients with multiple myeloma: towards a frailty approach?
Zweegman S; Engelhardt M; Larocca A;
Curr Opin Oncol; 2017 Sep; 29(5):315-321. PubMed ID: 28763310
[TBL] [Abstract][Full Text] [Related]
18. The prevalence and outcomes of frail older adults in clinical trials in multiple myeloma: A systematic review.
Mian H; McCurdy A; Giri S; Grant S; Rochwerg B; Winks E; Rosko AE; Engelhardt M; Pawlyn C; Cook G; Jackson G; Bringhen S; Facon T; Larocca A; Zweegman S; Wildes TM
Blood Cancer J; 2023 Jan; 13(1):6. PubMed ID: 36599867
[TBL] [Abstract][Full Text] [Related]
19. Development and validation of a chemotherapy tolerance prediction model for Chinese multiple myeloma patients: The TM frailty score.
Chen Y; Gu J; Huang B; Liu J; Li X; Li J
Front Oncol; 2023; 13():1103687. PubMed ID: 36741003
[TBL] [Abstract][Full Text] [Related]
20. Development of a new clinical index to easily assess frailty of elderly patients with multiple myeloma in Asian population.
Lee HS; Lee J; Jo JC; Jung SH; Lee JJ; Kim D; Lee S; Song K
Sci Rep; 2021 Nov; 11(1):22907. PubMed ID: 34824362
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
